Immunization, Hib3 in Upper middle income
Upper middle income: Immunization, Hib3 was 60.2% in 2024. ◆ Volatile
Immunization, Hib3 in Upper middle income, 1990–2024
Source: WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/). Measured in % of children ages 12-23 months.
Analysis
Upper middle income recorded 60.2% for immunization, hib3 in 2024. That is the highest value across all 35 years on record.
The figure is up 0.5% on the previous year and up 44.4% over ten years.
Over the whole period, immunization, hib3 in Upper middle income peaked at 60.2% in 2024 and was at its lowest, 0.0%, in 1990.
Upper middle income ranks 39th of 43 groups on this measure, in the bottom quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Immunization, Hib3 in Upper middle income, year by year
| Year | % of children ages 12-23 months | Change |
|---|---|---|
| 1990 | 0.0% | — |
| 1991 | 0.0% | — |
| 1992 | 0.0% | — |
| 1993 | 0.0% | — |
| 1994 | 0.0% | — |
| 1995 | 0.0% | — |
| 1996 | 0.0% | — |
| 1997 | 0.0% | — |
| 1998 | 2.2% | +4878.2% |
| 1999 | 3.5% | +56.1% |
| 2000 | 18.0% | +415.7% |
| 2001 | 18.1% | +0.4% |
| 2002 | 19.0% | +4.8% |
| 2003 | 20.6% | +8.7% |
| 2004 | 22.7% | +10.2% |
| 2005 | 23.9% | +5.2% |
| 2006 | 24.1% | +0.7% |
| 2007 | 26.7% | +10.8% |
| 2008 | 29.4% | +10.2% |
| 2009 | 29.3% | -0.3% |
| 2010 | 32.1% | +9.5% |
| 2011 | 33.6% | +4.8% |
| 2012 | 39.8% | +18.2% |
| 2013 | 38.5% | -3.1% |
| 2014 | 41.7% | +8.2% |
| 2015 | 50.8% | +21.9% |
| 2016 | 51.7% | +1.6% |
| 2017 | 50.9% | -1.5% |
| 2018 | 49.3% | -3.2% |
| 2019 | 51.3% | +4.0% |
| 2020 | 50.7% | -1.1% |
| 2021 | 51.7% | +1.9% |
| 2022 | 58.7% | +13.6% |
| 2023 | 59.9% | +2.0% |
| 2024 | 60.2% | +0.5% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 1990s | 0.6% | 0.0% | 3.5% | 10 |
| 2000s | 23.2% | 18.0% | 29.4% | 10 |
| 2010s | 44.0% | 32.1% | 51.7% | 10 |
| 2020s | 56.2% | 50.7% | 60.2% | 5 |
More health data for Upper middle income
- Population ages 35-39, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, male, annual growth rate 1.94 % change on previous year (2025)
- Population ages 40-44, female, per capita 0.0359 units per person (2025)
- Population ages 40-44, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, female, annual growth rate 1.71 % change on previous year (2025)
- Population ages 35-39, male, per capita 0.0413 units per person (2025)
- Population ages 35-39, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 35-39, male, annual growth rate 2.11 % change on previous year (2025)
- Population ages 35-39, female, per capita 0.0394 units per person (2025)
- Population ages 30-34, female, annual growth rate -3.39 % change on previous year (2025)
Frequently asked questions
- What is immunization, hib3 in Upper middle income?
- Immunization, hib3 in Upper middle income was 60.2% in 2024, according to WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).
- What is the highest immunization, hib3 recorded in Upper middle income?
- The highest recorded value was 60.2% in 2024.
- What is the lowest immunization, hib3 recorded in Upper middle income?
- The lowest recorded value was 0.0% in 1990.
- How does Upper middle income rank for immunization, hib3?
- Upper middle income ranks 39th out of 43 groups with data for 2024.
- Is immunization, hib3 rising or falling in Upper middle income?
- Over the last ten years it is up 44.4%. The long-run trend across the full record is volatile.
- Where does this Upper middle income data come from?
- The figures come from WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as part of Immunization, Hib3 (% of children ages 12-23 months). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 35 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.